참고문헌
- Bangsow C, Rubins N, Glusman G, et al (2001). The RUNX3 gene sequence, structure and regulated expression. Gene, 279, 221-32. https://doi.org/10.1016/S0378-1119(01)00760-0
- Chen G, Wang Z, Liu XY, Liu FY (2009). Adjuvant radiotherapy after modified Ivor-Lewis esophagectomy: can it prevent lymph node recurrence of the mid-thoracic esophageal carcinoma? Ann Thorac Surg, 87, 1697-702. https://doi.org/10.1016/j.athoracsur.2009.03.060
- Dresner SM, Griffin SM (2000). Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy. Br J Surg, 87, 1426-33. https://doi.org/10.1046/j.1365-2168.2000.01541.x
- Hiramatsu T, Osaki M, Ito Y, et al (2005). Expression of RUNX3 protein in human esophageal mucosa and squamous cell carcinoma. Pathobiology, 72, 316-24. https://doi.org/10.1159/000091329
- Ito K, Lim AC, Salto-Tellez M, et al (2008). RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell, 14, 226-37. https://doi.org/10.1016/j.ccr.2008.08.004
- Ito K, Liu Q, Salto-Tellez M, et al (2005). RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization. Cancer Res, 65, 7743-50. https://doi.org/10.1158/0008-5472.CAN-05-0743
- Kim HR, Oh BC, Choi JK, Bae SC (2008). Pim-1 kinase phosphorylates and stabilizes RUNX3 and alters its subcellular localization. J Cell Biochem, 105, 1048-58. https://doi.org/10.1002/jcb.21906
- Lau QC, Raja E, Salto-Tellez M, et al (2006). RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res, 66, 6512-20. https://doi.org/10.1158/0008-5472.CAN-06-0369
- Li QL, Ito K, Sakakura C, et al (2002). Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell, 109, 113-24. https://doi.org/10.1016/S0092-8674(02)00690-6
- Miyazono K, Suzuki H, Imamura T. (2003). Regulation of TGF-beta signaling and its roles in progression of tumors. Cancer Sci, 94, 230-34. https://doi.org/10.1111/j.1349-7006.2003.tb01425.x
- Nakagawa S, Kanda T, Kosugi S, et al (2004). Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg, 198, 205-11. https://doi.org/10.1016/j.jamcollsurg.2003.10.005
- Nevadunsky NS, Barbieri JS, Kwong J, et al (2009). RUNX3 protein is overexpressed in human epithelial ovarian cancer. Gynecol Oncol, 112, 325-30. https://doi.org/10.1016/j.ygyno.2008.09.006
- Sakakura C, Miyagawa K, Fukuda KI, et al (2007). Frequent silencing of RUNX3 in esophageal squamous cell carcinomas is associated with radioresistance and poor prognosis. Oncogene, 26, 5927-38. https://doi.org/10.1038/sj.onc.1210403
- Soong R, Shah N, Peh B.K, et al (2009). The expression of RUNX3 in colorectal cancer is associated with disease stage and patient outcome. Br J Cancer, 100, 676-9. https://doi.org/10.1038/sj.bjc.6604899
- Subramaniam MM, Chan JY, Soong R, et al (2009). RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. Breast Cancer Res Treat, 113, 113-21. https://doi.org/10.1007/s10549-008-9917-4
- Subramaniam MM, Chan JY, Soong R, et al (2009). RUNX3 inactivation in colorectal polyps arising through different pathways of colonic carcinogenesis. Am J Gastroenterol, 104, 426-36. https://doi.org/10.1038/ajg.2008.141
- Sugiura H, Ishiguro H, Kuwabara Y, et al (2008). Decreased expression of RUNX3 is correlated with tumor progression and poor prognosis in patients with esophageal squamous cell carcinoma. Oncol Rep, 19, 713-19.
- Sun ZG, Wang Z, Liu XY, Liu FY (2011). Mucin 1 and vascular endothelial growth factor C expression correlates with lymph node metastatic recurrence in patients with N0 esophageal cancer after Ivor-Lewis esophagectomy. World J Surg, 35, 70-7. https://doi.org/10.1007/s00268-010-0829-1
- Smith E, De Young NJ, Pavey SJ, et al (2008). Similarity of aberrant DNA methylation in Barrett's esophagus and esophageal adenocarcinoma. Mol Cancer, 7, 75. https://doi.org/10.1186/1476-4598-7-75
- Tonomoto Y, Tachibana M, Dhar D.K, et al (2007). Differential expression of RUNX genes in human esophageal squamous cell carcinoma: downregulation of RUNX3 worsens patient prognosis. Oncology, 73, 346-56. https://doi.org/10.1159/000135350
- Torquati A, O'rear L, Longobardi L, et al (2004). RUNX3 inhibits cell proliferation and induces apoptosis by reinstating transforming growth factor beta responsiveness in esophageal adenocarcinoma cells. Surgery, 136, 310-6. https://doi.org/10.1016/j.surg.2004.05.005
- Wang S, Liu H, Akhtar J, Chen HX, Wang Z (2013). Alteration of runt-related transcription factor 3 gene expression and biologic behavior of esophageal carcinoma TE-1 cells after 5-azacytidine intervention. Asian Pac J Cancer Prev, 14, 5427-33. https://doi.org/10.7314/APJCP.2013.14.9.5427
- Won YW, Lee M, Kim HA, Bull DA, Kim SW (2003). Hypoxiainducible plasmid expressing both miSHP-1 and HO-1 for the treatment of ischemic disease. J Control Release, 11, 22-8.
피인용 문헌
- Inactivation of RUNX3 predicts poor prognosis in esophageal squamous cell carcinoma after Ivor-Lewis esophagectomy vol.31, pp.12, 2014, https://doi.org/10.1007/s12032-014-0309-9
- Baicalein increases the expression and reciprocal interplay of RUNX3 and FOXO3a through crosstalk of AMPKα and MEK/ERK1/2 signaling pathways in human non-small cell lung cancer cells vol.34, pp.1, 2015, https://doi.org/10.1186/s13046-015-0160-7
- Downregulation of RUNX3 moderates the frequency of Th17 and Th22 cells in patients with psoriasis vol.13, pp.6, 2016, https://doi.org/10.3892/mmr.2016.5108
- RUNX3 reverses cisplatin resistance in esophageal squamous cell carcinoma via suppression of the protein kinase B pathway vol.7, pp.5, 2016, https://doi.org/10.1111/1759-7714.12370